Inactive Instrument

Highlights ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13	AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	Feb. 13	MT
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	Feb. 12	MT
AbbVie Acquires ImmunoGen for $31.26 per Share	Feb. 12	MT
AbbVie: acquisition of ImmunoGen finalized	Feb. 12	CF
AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	Feb. 11	CI
AbbVie 4Q Sales Lower as Himura Revenue Sinks	Feb. 02	DJ
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02	RE
Drugmakers kick off industry conference with two cancer deals	Jan. 08	RE
J&J to buy cancer therapy developer Ambrx for $2 bln	Jan. 08	RE
2023 highlights of the stock market year	Dec. 21
BioMarin settles with Elliott, adds 3 independent directors	Dec. 20	RE
ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	Dec. 10	CI
AbbVie-Cerevel Deal Makes 'Strategic Sense,' Mizuho Says	Dec. 07	MT
Trending : AbbVie to Buy Cerevel for $45 a Share	Dec. 07	DJ
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout	Dec. 07	RE
AbbVie to buy drug developer Cerevel for $8.7 billion	Dec. 06	RE
AbbVie to Buy Cerevel Therapeutics for $8.7 Billion -- Update	Dec. 06	DJ
ImmunoGen Says FDA Grants Priority Review to Application Seeking Full Approval of Ovarian Cancer Treatment	Dec. 05	MT
FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer	Dec. 05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Highlights

Filters